Summary
The Food and Drug Administration is reviewing data suggesting a possible link between the diabetes medication Actos and bladder cancer.
The agency says five-year results from an ongoing study show patients taking Actos the longest had a higher risk of bladder cancer. The drug's manufacturer, Takeda Pharmaceuticals, is conducting the study, which is scheduled to run 10 years. Sales of Actos have surged in recent years because it is seen as a safer alternative to GlaxoSmithKline's diabetes drug Avandia.See the full content of this document
Extract
Fda Reviewing Cancer Risk with Diabetes Pill Actos
The FD...
See the full content of this document
Sponsored links
